Larry Mathis Financial Planning LLC Buys Shares of 2,100 Elevance Health, Inc. $ELV

Larry Mathis Financial Planning LLC acquired a new position in shares of Elevance Health, Inc. (NYSE:ELV) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 2,100 shares of the company’s stock, valued at approximately $736,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rossby Financial LCC grew its holdings in shares of Elevance Health by 110.0% during the third quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after buying an additional 44 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new position in shares of Elevance Health during the fourth quarter valued at approximately $31,000. J.Safra Asset Management Corp purchased a new position in shares of Elevance Health during the fourth quarter valued at approximately $32,000. ORG Partners LLC boosted its position in Elevance Health by 120.4% during the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after acquiring an additional 59 shares during the last quarter. Finally, Dorato Capital Management purchased a new stake in Elevance Health in the 4th quarter worth approximately $41,000. 89.24% of the stock is currently owned by hedge funds and other institutional investors.

Elevance Health Price Performance

ELV stock opened at $388.77 on Friday. The firm has a market cap of $84.43 billion, a P/E ratio of 16.54, a price-to-earnings-growth ratio of 2.20 and a beta of 0.67. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $426.98. The stock has a 50-day simple moving average of $375.30 and a 200-day simple moving average of $346.91.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating the consensus estimate of $10.74 by $1.84. The business had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The business’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, equities analysts predict that Elevance Health, Inc. will post 26.93 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be given a $1.72 dividend. The ex-dividend date of this dividend is Wednesday, June 10th. This represents a $6.88 annualized dividend and a dividend yield of 1.8%. Elevance Health’s payout ratio is presently 29.26%.

Insider Activity

In related news, Director Robert L. Dixon, Jr. sold 151 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $401.77, for a total value of $60,667.27. Following the completion of the sale, the director directly owned 10,734 shares of the company’s stock, valued at $4,312,599.18. The trade was a 1.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

ELV has been the subject of several analyst reports. Barclays upped their target price on Elevance Health from $408.00 to $480.00 and gave the company an “overweight” rating in a research note on Tuesday, May 26th. Morgan Stanley raised their price target on Elevance Health from $352.00 to $404.00 and gave the stock an “equal weight” rating in a research note on Thursday, June 4th. Jefferies Financial Group lowered their price target on Elevance Health from $395.00 to $391.00 and set a “buy” rating for the company in a report on Monday, April 20th. Bank of America upped their price objective on shares of Elevance Health from $435.00 to $460.00 and gave the company a “buy” rating in a research note on Thursday, June 4th. Finally, Truist Financial increased their price objective on shares of Elevance Health from $375.00 to $450.00 and gave the stock a “buy” rating in a report on Monday, June 1st. Fourteen research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, Elevance Health presently has an average rating of “Moderate Buy” and a consensus price target of $416.11.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.